登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000516 证券简称：国际医学 公告编号：2025-041 西安国际医学投资股份有限公司关于召开2025年第一次临时股东会的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 2.召集人：西安国际医学投资股份有限公司董事会。 3.公司第十三届董事会第六次会议审议通过了关于召开公司2025年第一次临时股东会的事项。会议的召 开符合《公司法》《上市公司股东会规则》《股票上市规则》等有关法律法规、规范性文件的规定和 《公司章程》的要求。 4.会议召开时间： 现场会议时间：2025年9月8日（星期一）下午2:45； 网络投票时间：2025年9月8日。 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为： 2025年9月8日的交易时间，即09:15一09:25，09:30一11:30和13:00一15:00；通过深圳证券交易所互联网 系统投票的具体时间为：2025年9月8日09:15一15:00期间任意时间。 5.会议的召开方式：现场表决和网络投票相结合的方式。 本公司于2025年8月22日在《 ...

Core Points - The company held its 38th meeting of the 10th Board of Directors on June 20, 2025, where several key resolutions were passed [1][2] - The Board approved the proposal to amend the Articles of Association and abolish the Supervisory Board, which will be submitted to the shareholders' meeting for approval [1][2] - The Board also approved amendments to the Independent Director Work System, Shareholders' Meeting Rules, and Board Meeting Rules, all of which will be submitted to the shareholders' meeting [2][3] - The Board nominated candidates for the 11th Board of Directors, including non-independent directors and independent directors, who will also be voted on at the shareholders' meeting [4][5][6][7][8] Summary by Sections Board Meeting Resolutions - The meeting was convened in compliance with the Company Law and Articles of Association, with all six attending directors voting unanimously on the proposals [1] - The proposal to abolish the Supervisory Board received 6 votes in favor, with no opposition or abstentions [1][2] - The amendments to the Independent Director Work System and the meeting rules were also approved with unanimous support [2] Director Nominations - The Board nominated Mr. Ma Hongwei, Ms. Jiang Haiying, and Ms. Luo Ling as candidates for non-independent directors, all of whom meet the legal requirements for directorship [4][5] - Independent director candidates include Mr. Feng Qiaogen, Ms. Tang Zhen, and Mr. Han Jian, all of whom possess the necessary qualifications and have no conflicts of interest with the company [6][7][8] Other Proposals - The Board approved the revision of the Compensation and Assessment Management Measures with unanimous support [9] - A proposal to hold the first extraordinary shareholders' meeting of 2025 was also approved, with details to be disclosed in relevant financial publications [9]